Teknova Announces Time Change for First Quarter 2023 Financial Results Conference Call on May 10, 2023

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

HOLLISTER, Calif., May 04, 2023 (GLOBE NEWSWIRE) — Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company has changed the timing of its previously announced first quarter 2023 financial results webcast and conference call to 5:30 p.m. Eastern Time on Wednesday, May 10, 2023.

Participants can access the live webcast on the Investor Relations section of the Teknova website and at this link: https://edge.media-server.com/mmc/p/tquygjuv. To receive a PIN number for dial in, participants can register for the webcast via this link: https://register.vevent.com/register/BIaab243465e1942deb84daf92e4eb35d8. The webcast will be available for replay on the Company’s website approximately two hours after the event.

About Teknova
Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel therapies that will help people live longer, healthier lives. We offer fully customizable solutions for every stage of the workflow, supporting industry leaders in cell and gene therapy, molecular diagnostics, and synthetic biology. Our fast turnaround of high-quality agar plates, microbial culture media, buffers and reagents, and water helps our customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 200,000 square feet of state-of-the-art facilities, Teknova’s modular manufacturing platform was designed by our team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of novel therapies.

CONTACT: Investor Contacts 
Matt Lowell 
Chief Financial Officer 
matt.lowell@teknova.com
+1 831-637-1100 

Sara Michelmore 
MacDougall Advisors 
smichelmore@macdougall.bio 
+1 781-235-3060 

Media Contact 
Jennifer Henry  
Senior Vice President, Marketing 
jenn.henry@teknova.com  
+1 831-313-1259 

Staff

Recent Posts

Introducing Lumelight: New Benefits Provider Launches to Help U.S. Employers Manage Growing Regulatory Demands

New Company Unites Compliance, Claims and Analytics Providers Backed by Water Street Healthcare Partners, Lumelight Appoints…

1 second ago

Griffin Health improves patient safety, prevents HAIs with implementation of BioVigil electronic hand hygiene system

ANN ARBOR, Mich., June 10, 2025 /PRNewswire/ -- Six months after implementing BioVigil's electronic hand…

6 seconds ago

Inflammatix Names Martín Vazquez as Chief Operating Officer to Drive National Scale-Up of TriVerity™ Test System

Seasoned medtech executive joins as hospital adoption accelerates for breakthrough diagnostic in acute infection and…

9 seconds ago

hellocare.ai Enters into Collaboration with Mayo Clinic for AI Co-Innovation Project

CLEARWATER, Fla., June 10, 2025 /PRNewswire/ -- hellocare.ai, a leading AI-assisted virtual care delivery platform…

14 seconds ago

ScaleReady Announces a G-Rex® Grant has been awarded to Immuneel Therapeutics

ST. PAUL, Minn., June 10, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing,…

18 seconds ago

Evogene Announces Completion of First-In-Class Foundation Model for Generative Molecule Design, Developed in Collaboration with Google Cloud

The new model addresses the challenge of identifying novel small molecules that meet multiple product…

21 seconds ago